Other
Apr 2018MIT terminated its subcontract with Nectome after public controversy over the company's fatal brain-preservation claims.
SourceBuilding a way to preserve long-term memories.
Company research
Public company, workplace, funding, and market signals
Overview
Nectome is a neuroscience/biotechnology startup focused on whole-body, whole-brain post-mortem preservation intended to preserve the connectome and information needed for possible future revival.
Primary product
Whole-body, whole-brain post-mortem preservation service for potential future revival
Founded
2015
Headquarters
Vancouver, Washington, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Brain preservation / neurotechnology
Business model
direct-to-consumer preservation services
pre-sale preservation contracts
research and validation publications
Funding
Stage
Seed / venture
Total raised
$275K
Latest round
Seed · Feb 2024
Latest amount
$30K
People & investors
Leadership
Robert McIntyre
CEO / Co-founder
Co-founder
Chief Scientific Officer
Research Associate
Founder/CEO
Work & culture
Highly research-driven and validation-focused; public posts emphasize independent verification, scientific rigor, transparency, and long-term organizational stability.
Benefits
whole-body, whole-brain preservation
compatible with traditional funerals at room temperature
cold storage stability for hundreds of years
no liquid-nitrogen dependence
planned, scheduled procedure rather than emergency response
Product & market
Pricing
Direct sale of one preservation per contract; public posts say no memberships or insurance, with full-price sales at $250,000.
Differentiators
- —whole-body, whole-brain preservation instead of brain-only storage
- —room-temperature compatibility for traditional funerals
- —long-term cold storage around -32°C rather than liquid nitrogen
- —publicly emphasized ~12-minute post-mortem perfusion window
- —heavy use of independent validation and published research
- —planned MAiD-compatible procedure rather than emergency response
Technology
aldehyde-stabilized cryopreservation (ASC)
glutaraldehyde fixation
cryoprotectant perfusion
electron microscopy
whole-brain CT imaging
Google Analytics
Intercom
Segment
Substack
Customers
terminally ill individuals
their families or loved ones
people seeking pre-arranged preservation
Competitors
Alcor Life Extension Foundation
Cryonics Institute
Tomorrow Bio
KrioRus
Oregon Cryonics
BlackFrog Technologies
Scale & contact
Estimated revenue
~$1M ARR (public estimate)
Estimated monthly visits
16.2K
Traffic estimate as of May 2026
Signals & risks
Latest news
Nectome's Substack · Apr 2026
Discusses long-term care, Oregon operations, for-profit structure, endowment thinking, and legal-risk planning.
New Scientist · Mar 2026
Mainstream coverage of the pig-brain preservation work and Nectome's plans to offer the protocol to terminally ill people in Oregon.
Nectome's Substack · Mar 2026
Details the 12-minute post-mortem window, scheduled MAiD-compatible procedures, and whole-body preservation claims.
Nectome's Substack · Mar 2026
Explains Nectome's direct-sales model, lack of memberships or insurance, and public full-price sales of $250k.
bioRxiv · Mar 2026
Nectome researchers reported near-perfect preservation results in pigs, including a roughly 14-minute perfusability window and connectomically traceable whole brains.
Jobs and careers at Nectome
0 jobs at Nectome
No open positions
Check back later for new openings